News
Public · Published
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
Clearmind Medicine completed patient recruitment for the first segment of Part B of its Phase I/IIa trial of CMND-100 in patients with moderate-to-severe alcohol use disorder. Part B has two single-dose groups, 80 mg and 160 mg, with six patients each.
Published:
Updated:
What happened
Clearmind Medicine completed patient recruitment for the first segment of Part B of its Phase I/IIa trial of CMND-100 in patients with moderate-to-severe alcohol use disorder. Part B has two single-dose groups, 80 mg and 160 mg, with six patients each.
Confirmed
Global impact / market context
Recruiting patients is a required step before a drug can be tested in people with the target condition. Reaching this point keeps the company's development timeline moving, but the treatment still must show safety and usefulness in later results before it could reach patients.
Analyst inference
Clinical-stage drug developers often spend cash for years before earning product revenue, so trial progress can shape how investors judge funding needs and risk. This trial runs at named medical centers in the United States and Israel, which may support how the program is viewed.
Analyst inference
What to watch
- The first Part B group is a single-dose group of six patients at 80 mg, and the second is six patients at 160 mg; both assess safety, tolerability, pharmacokinetics and early efficacy signals. Confirmed
- Watch for company statements on whether recruitment for the second Part B group proceeds and whether early craving-reduction signals are reported, since the article does not set dates for these steps. Proposed
- Because the company is clinical-stage and has no approved product mentioned, investors may focus on trial spending and any future need to raise money, which could affect cash available and ownership. Analyst inference